Equities analysts expect ZIOPHARM Oncology Inc (NASDAQ:ZIOP) to announce ($0.13) earnings per share (EPS) for the current quarter, according to Zacks. Four analysts have made estimates for ZIOPHARM Oncology’s earnings. The lowest EPS estimate is ($0.14) and the highest is ($0.13). ZIOPHARM Oncology posted earnings per share of ($0.11) in the same quarter last year, which suggests a negative year-over-year growth rate of 18.2%. The firm is expected to issue its next earnings results on Wednesday, November 8th.
On average, analysts expect that ZIOPHARM Oncology will report full year earnings of ($0.55) per share for the current financial year, with EPS estimates ranging from ($0.56) to ($0.54). For the next year, analysts expect that the firm will report earnings of ($0.59) per share, with EPS estimates ranging from ($0.65) to ($0.53). Zacks Investment Research’s earnings per share calculations are an average based on a survey of analysts that follow ZIOPHARM Oncology.
ZIOPHARM Oncology (NASDAQ:ZIOP) last announced its earnings results on Monday, July 31st. The biotechnology company reported ($0.13) EPS for the quarter, meeting the consensus estimate of ($0.13). The company had revenue of $1.60 million for the quarter, compared to analysts’ expectations of $1.66 million. The business’s quarterly revenue was down 5.9% compared to the same quarter last year. During the same quarter in the previous year, the business posted ($1.01) earnings per share.
ZIOP has been the subject of several research analyst reports. HC Wainwright set a $10.00 price objective on ZIOPHARM Oncology and gave the stock a “buy” rating in a research report on Tuesday, August 1st. BidaskClub raised ZIOPHARM Oncology from a “sell” rating to a “hold” rating in a research report on Tuesday, August 8th. Finally, ValuEngine raised ZIOPHARM Oncology from a “sell” rating to a “hold” rating in a report on Monday, August 28th. Two investment analysts have rated the stock with a sell rating, one has given a hold rating and two have given a buy rating to the company. ZIOPHARM Oncology has an average rating of “Hold” and an average target price of $16.50.
Shares of ZIOPHARM Oncology (NASDAQ:ZIOP) traded up 4.24% during midday trading on Tuesday, hitting $4.67. The company had a trading volume of 1,562,315 shares. The company’s 50 day moving average is $5.98 and its 200 day moving average is $6.17. ZIOPHARM Oncology has a one year low of $4.40 and a one year high of $7.88. The firm’s market cap is $656.75 million.
TRADEMARK VIOLATION WARNING: This article was originally published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this article on another website, it was stolen and republished in violation of United States & international copyright law. The legal version of this article can be read at https://www.dispatchtribunal.com/2017/11/12/brokerages-expect-ziopharm-oncology-inc-ziop-to-announce-0-13-earnings-per-share.html.
A number of institutional investors have recently bought and sold shares of ZIOP. Wells Fargo & Company MN grew its stake in shares of ZIOPHARM Oncology by 5.5% in the 1st quarter. Wells Fargo & Company MN now owns 199,406 shares of the biotechnology company’s stock valued at $1,264,000 after purchasing an additional 10,424 shares during the period. Bank of New York Mellon Corp grew its stake in shares of ZIOPHARM Oncology by 1.6% in the 1st quarter. Bank of New York Mellon Corp now owns 598,406 shares of the biotechnology company’s stock valued at $3,794,000 after purchasing an additional 9,652 shares during the period. UBS Asset Management Americas Inc. grew its stake in shares of ZIOPHARM Oncology by 79.6% in the 1st quarter. UBS Asset Management Americas Inc. now owns 37,687 shares of the biotechnology company’s stock valued at $239,000 after purchasing an additional 16,700 shares during the period. Parametric Portfolio Associates LLC grew its stake in shares of ZIOPHARM Oncology by 325.7% in the 1st quarter. Parametric Portfolio Associates LLC now owns 81,011 shares of the biotechnology company’s stock valued at $514,000 after purchasing an additional 61,979 shares during the period. Finally, American International Group Inc. grew its stake in shares of ZIOPHARM Oncology by 7.1% in the 1st quarter. American International Group Inc. now owns 74,843 shares of the biotechnology company’s stock valued at $475,000 after purchasing an additional 4,951 shares during the period. 41.91% of the stock is owned by hedge funds and other institutional investors.
About ZIOPHARM Oncology
ZIOPHARM Oncology, Inc is a biopharmaceutical company, which is seeking to develop, acquire and commercialize, on its own or with partners, a portfolio of cancer therapies that address unmet medical needs. The Company is focused on developing products in immuno-oncology that employ gene expression, control and cell technologies to deliver cell- and viral-based therapies for the treatment of cancer and graft-versus-host-disease.
Get a free copy of the Zacks research report on ZIOPHARM Oncology (ZIOP)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for ZIOPHARM Oncology Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ZIOPHARM Oncology Inc and related companies with MarketBeat.com's FREE daily email newsletter.